Joel L Spivack is a Pomona, New York based male podiatrist who is specialized in Podiatry. Active license number of Joel L Spivack for Podiatry is N0026261 in New York. Joel L Spivack is qualified with a Doctor of Podiatric Medicine (D.P.M.) degree, licensed by the state, and practicing within the scope of that license. He diagnose and treat foot diseases and deformities. He can perform medical, surgical and other operative procedures, prescribe corrective devices and prescribe and administer drugs and physical therapy.
Complete Profile:
Joel L Spivack speciality, credentials, practice address, contact phone number and fax are as below.
Patients can directly walk in or can call on the below given phone number for appointment.
Specialization:
Podiatrist
Credentials:
DPM
Gender:
Male
Practice Address:
978 Rte 45 Rm 109, Pomona, New York, 10970
Phone:
845-354-2700
Fax:
845-354-2809
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details are as mentioned below.
NPI Number:
1114066313
NPI Enumeration Date:
05 Feb, 2007
NPI Last Update On:
08 Jul, 2007
Medical Licenses:
Doctors can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Joel L Spivack are as mentioned below.
License Number
Specialization
State
Status
N0026261
Podiatry
New York
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
978 Rte 45 Rm 109, Ste 109 Pomona, New York
Zip:
10970
Phone Number:
845-354-2700
Fax Number:
845-354-2809
Patients can reach Joel L Spivack at 978 Rte 45 Rm 109, Pomona, New York or can call to book an appointment on 845-354-2700. Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 November, 2024.